Neuraminidase inhibitors in prophylaxis and treatment of influenza;Inhibitory neuraminidazy w profilaktyce i leczeniu grypy

Polski Merkuriusz Lekarski

Volumn 25, Issue 145, 2008, Pages 67-73

  Nitsch Osuch, Aneta ^a   Brydak, Lidia B ^a,b   Wardyn, Andrzej K ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b National Influenze Center

Author keywords

Influenza; Neuraminidase inhibitors; Oseltamivir; Zanamivir

Indexed keywords

ANTIVIRUS AGENT; ENZYME INHIBITOR; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ARTICLE; DRUG ADMINISTRATION; DRUG ANTAGONISM; EPIDEMIC; HUMAN; INFLUENZA; INFLUENZA VIRUS A H5N1;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; ZANAMIVIR;

EID: 50049094523     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aoki F.Y., Macleod M.D.: Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother., 2003, 51, 123-129.
2. Beigel J.H., Farrar J., Han M.: Writing Committee of the World Health Organization Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med., 2005, 353, 1374-1385.
3. Bradley S.F.: Prevention of influenza in long-term-care facilities. Long-Term-Care Committee of the Society for Health-care Epidemiology of America. Infect. Control. Hosp. Epidemiol., 1999, 20, 629-637.
4. Brydak L.B.: Grypa i jej profilaktyka. Termedia, Poznań 2004.
5. Brydak LB.: Grypa - problem zdrowia publicznego. Prakt. Lek., 2007, 8, 3-9.
6. Cass L.M., Brown J., Pickford M.: Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin. Pharmacokinet., 1999, 36, supl. 1, 21-31.
7. Cooper N.J., Sutton A.J., Abrams K.R.: Efficacy and safety of the neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomized controlled trails. BMJ, 2003, 326, 12-35.
8. www.ecdc.eu.int/.
9. Hayden F.G., Osterhaus A.D., Treanor J.J.: Efficacy and safety of neuraminidase inhibitor zanamivir in the treatment of influenza virus infection. N. Engl. J. Med., 1997, 337, 874-880.
10. Hedrick J.A., Barzilai A., Behre U.: Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J., 2000, 19, 410-417.
11. Human health issues related to avian influenza in Canada. www.phacaspc.gc.ca
12. Ilyushina N.: Combination therapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res., 2006, 70, 121-131.
13. Izumi Y., Tokuda K.: Neuroexcitatory actions of Tamiflu and is carboxylate metabolite. Neurosci. Lett., 2007, 426(1), 54-58.
14. Kaiser L., Wat S., Mills T.: Impact of oseltamivir on influenza-related lower respiratory tract complications and hospitalizations. Arch. Int. Med., 2003, 163, 1667-1672.
15. Krajowy plan dla Polski na wypadek wystapienia kolejnej pandemii grypy.
16. Lye D., Ang B.: Review of human infections with avian influenza H5N1 and proposed local clinical management guidline. Ann. Acad. Med. Singapore, 2007, 36, 285-292.
17. Makela M.J., Pauksen K.: Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double blind, placebo controlled European study. J. Infect., 2000, 40, 42-48.
18. Matsumoto K., Ogawa N.: Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. Antivir. Ther., 1999, 4, 61-81.
19. McKimm_Breschin J.L., Selleck P., Usman T., Johnson M.: Reduced sensitivity of influenza A (H1N1) to oseltamivir. Emerg. Infect. Dis., 2007, 13, 1354-1357.
20. Monto A.S., Fleming D.H. Henry D.: Efficacy and safety of neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infection. J. Infect. Dis., 1999, 180, 254-261.
21. Moscona A.: Neuraminidase inhibitors for influenza. N Eng. J.Med., 2005, 353(13), 1363-1368.
22. Murphy K.R., Eividson A.: Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma and chronic obstructive pulmonary disease: a double blind, randomized, placebo-controlled, multicentre study. Clin. Drug Invest., 2000, 20, 337-349.
23. Nicholson K.G., Aoki F.Y.: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet, 2000, 355, 1845-1850.
24. Pandemic inluenza: science to policy. The Royal Society & the Academy of Medical Sciences, 2006.
25. Perspectives in Interpandemic Influenza. 12-14 października 2007, Madryt, Hiszpania (materiaty zjazdowe).
26. Peters P.H., Gravenstein S., Norwood P.: Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated trial older population. J. Am. Geriatr. Soc., 2001, 49, 1025-1031.
27. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 2006, 55 (No-RR-10), 1-42.
28. Reece P.A.: Neuraminidase inhibitor resistance in influenza viruses. J. Medical. Virol., 2007, 79, 1577-1586.
29. Smolik S., Weglarz L.: Molekularne mechanizmy aktywności farmakologicznej inhibitorów neuraminidazy stosowanych w zakażeniach wywołanych wirusem grypy. Ann. Acade. Med. Siles., 2007, 61(2), 146-152.
30. Terada K., Kawai Y, Manju A.: Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr. Infect. Dis., 2008, 27(1), 88-89.
31. The MIST (Management of Influenza in the Southern Hemisphere Trailist) Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infection. Lancet, 1998, 352, 1877-1881.
32. Treanor J.J., Hayden F.G., Vrooman P.S.: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA, 2000, 283, 1016-1024.
33. US Department of Health and Human Services. HHS pandemic influenza plan. 8 November 2005.
34. Ward P., Small I., Smith J.: Oseltamivir (Tamiflu) and its potential for use in the event o fan influenza pandemic. J. Antimicrob. Chemother., 2005, 55, 5-21.
35. Welliver R., Monto A.S., Carewicz O.: Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA, 2001, 285, 748-754.
36. Whitley R.J., Hayden F.G., Resinger K.S.: Oral oseltamivir treatment of influenza in children. Pediatr, Infect Dis. J., 2001, 20, 127-133.
37. www.idsociety.org/pandemicinfluenza/.
38. www.who.int/csr/disease/avian_influenza/en/.
39. www.who.int/csr/disease/avian_influenza/guidelines/clinicalmanage07/en/.
40. Yuen K.Y., Wong S.S.: Human infection by avian influenza H5N1. Hong Kong Med. J., 2005, 11, 189-199.